
ABUS
Healthcare · Biotechnology · $627.0M market cap
$4.09+0.06 (+1.5%)Nov 13, 4:00 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -3.7% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 10, 2026 | Before the open | -0.03 | 0.42 | +1613.6% |
| Aug 12, 2026 | Before the open | -0.03 | -0.03 | 0.0% |
| May 13, 2026 | Before the open | -0.05 | 1.19 | +2480.0% |
| Feb 26, 2026 | Time not confirmed | -0.03 | -0.01 | +54.3% |
| Nov 13, 2025 | Before the open | -0.05 | -0.06 | -20.0% |
| Aug 6, 2025 | Before the open | -0.09 | 0.01 | +111.1% |
| May 14, 2025 | Before the open | -0.15 | -0.18 | -20.0% |
| Feb 26, 2025 | Before the open | -0.12 | -0.10 | +14.5% |
| Nov 6, 2024 | Before the open | -0.13 | -0.14 | -7.7% |
| Aug 1, 2024 | Before the open | -0.13 | -0.15 | -15.4% |
| May 2, 2024 | Before the open | -0.15 | -0.14 | +6.7% |
| Feb 29, 2024 | Before the open | -0.12 | -0.12 | 0.0% |
| Nov 7, 2023 | Before the open | -0.15 |
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral…
| -0.16 |
| -6.7% |
| Aug 3, 2023 | Before the open | -0.14 | -0.13 | +7.1% |
| May 4, 2023 | Before the open | -0.18 | -0.14 | +22.2% |
| Mar 2, 2023 | Before the open | -0.13 | -0.14 | -7.7% |
| Nov 9, 2022 | Before the open | -0.18 | -0.16 | +11.1% |
| Aug 4, 2022 | Before the open | -0.15 | -0.13 | +13.3% |
| May 5, 2022 | Before the open | -0.20 | -0.14 | +30.0% |
| Mar 3, 2022 | Before the open | -0.19 | -0.15 | +21.1% |
| Nov 4, 2021 | Before the open | -0.29 | -0.30 | -3.4% |
| Aug 5, 2021 | Before the open | -0.29 | -0.29 | 0.0% |
| May 5, 2021 | Before the open | -0.30 | -0.26 | +13.3% |
| Mar 4, 2021 | Before the open | -0.22 | -0.23 | -4.5% |
| Nov 5, 2020 | Before the open | -0.30 | -0.35 | -16.7% |
| Aug 7, 2020 | Before the open | -0.31 | -0.33 | -6.5% |
| May 11, 2020 | Before the open | -0.31 | -0.25 | +19.4% |
| Mar 5, 2020 | Before the open | -0.32 | -0.53 | -65.6% |
| Nov 6, 2019 | Before the open | -0.39 | -0.51 | -30.8% |
| Aug 5, 2019 | Before the open | -0.48 | -0.61 | -27.1% |
| May 6, 2019 | After the close | -0.40 | -0.63 | -57.5% |
| Mar 7, 2019 | After the close | -0.40 | -0.37 | +7.5% |
| Nov 7, 2018 | After the close | -0.54 | -0.39 | +27.8% |
| Aug 2, 2018 | After the close | -0.53 | -0.57 | -7.5% |
| May 3, 2018 | After the close | -0.53 | -0.46 | +13.2% |
| Mar 14, 2018 | After the close | -0.39 | -0.90 | -130.8% |